Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Universal Screening and Drug Treatment of Dyslipidemia in Children and Adolescents

Universal Screening and Drug Treatment of Dyslipidemia in Children and Adolescents VIEWPOINT ONLINE FIRST Scan for Author Audio Interview Universal Screening and Drug Treatment of Dyslipidemia in Children and Adolescents sion of treatment to intermediate-risk persons. As a result of Bruce M. Psaty, MD, PhD these findings and recommendations, the use of statins and Frederick P. Rivara, MD, MPH their indications have expanded. By 2005, an estimated 30 mil- lion Americans were taking statins, and in 2009, both simva- VER THE LAST FEW DECADES, THE THEORY THAT statin and atorvastatin were among the top 5 products dis- adult diseases begin in childhood has been widely pensed. The expert panel’s recommendations for the use of discussed. Smoking, the most common underly- drugtherapiesinchildrenaresimplypartofthishistoricaltrend. Oing cause of death for adults in the United States, Both the expanded use of statins in new populations and the begins before the age of 18 years in the majority of adult smok- effort to achieve additional lipid lowering in high-risk patients ers. Obesity has become the largest health problem in the increase the opportunities for benefits and for harms. United States, and the difficulty of long-term weight loss for As a drug class, the statins are not harmless. For in- obese children and adolescents means that many http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Universal Screening and Drug Treatment of Dyslipidemia in Children and Adolescents

JAMA , Volume 307 (3) – Jan 18, 2012

Loading next page...
 
/lp/american-medical-association/universal-screening-and-drug-treatment-of-dyslipidemia-in-children-and-wDBfrvsHlZ
Publisher
American Medical Association
Copyright
Copyright 2012 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2011.1916
pmid
22174386
Publisher site
See Article on Publisher Site

Abstract

VIEWPOINT ONLINE FIRST Scan for Author Audio Interview Universal Screening and Drug Treatment of Dyslipidemia in Children and Adolescents sion of treatment to intermediate-risk persons. As a result of Bruce M. Psaty, MD, PhD these findings and recommendations, the use of statins and Frederick P. Rivara, MD, MPH their indications have expanded. By 2005, an estimated 30 mil- lion Americans were taking statins, and in 2009, both simva- VER THE LAST FEW DECADES, THE THEORY THAT statin and atorvastatin were among the top 5 products dis- adult diseases begin in childhood has been widely pensed. The expert panel’s recommendations for the use of discussed. Smoking, the most common underly- drugtherapiesinchildrenaresimplypartofthishistoricaltrend. Oing cause of death for adults in the United States, Both the expanded use of statins in new populations and the begins before the age of 18 years in the majority of adult smok- effort to achieve additional lipid lowering in high-risk patients ers. Obesity has become the largest health problem in the increase the opportunities for benefits and for harms. United States, and the difficulty of long-term weight loss for As a drug class, the statins are not harmless. For in- obese children and adolescents means that many

Journal

JAMAAmerican Medical Association

Published: Jan 18, 2012

References